Targets › PDGFRA
32 programs from 31 companies in 125 trials: 61 Phase 2, 44 Phase 1, 19 Phase 3, 1 Phase 4; Oncology, Gastroenterology, Respiratory; next expected readout Dec 2026.
Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. (UniProt, P16234)
Open in Phaseline: the race on PDGFRA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Blueprint Medicines | Avapritinib (BLU-285) Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor | KIT, PDGFRA | Phase 4 | Mastocytosis, Systemic; Indolent Systemic Mastocytosis; AML (Acute Myelogenous Leukemia); Anatomic Stage IV Breast Cancer AJCC v8 … | Jun 2027 |
| Gossamer Bio USA | Seralutinib Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Macrophage colony stimulating factor receptor inhibitor | KIT, PDGFRB, PDGFRA, CSF1R | Phase 3 | Pulmonary Arterial Hypertension | Dec 2026 |
| Deciphera Pharmaceuticals | Vimseltinib (DCC-3014) KIT/PDGFRA/CSF1R inhibitor | CSF1R, KIT, PDGFRA | Phase 3 | Tenosynovial Giant Cell Tumor; Chronic Graft-Versus-Host Disease (cGVHD); Healthy Participants; Healthy Male Participants … | Dec 2026 |
| Exelixis | Zanzalintinib (XL092) Multi-targeted tyrosine kinase inhibitor targeting FGFR, MET, ROS1, and AXL | FGFR1, FGFR2, FGFR3, FGFR4, MET, KIT, PDGFRA | Phase 3 | Non-Clear Cell Renal Cell Carcinoma; Colorectal Cancer; Meningioma; Head and Neck Squamous Cell Carcinoma … | Dec 2026 |
| Deciphera Pharmaceuticals | Ripretinib Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor | KIT, PDGFRA | Phase 3 | GIST; Gastrointestinal Stromal Tumors | Mar 2027 |
| Daiichi Sankyo | Quizartinib Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor | CSF1R, FLT3, KIT, PDGFRB, PDGFRA | Phase 3 | Leukemia; Acute Myeloid Leukemia; Hepatic Impairment; Acute Myeloid Leukemia, Adult … | May 2027 |
| Jiangsu HengRui Medicine | Famitinib Stem cell growth factor receptor inhibitor; Vascular endothelial growth factor receptor 1 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | KIT, FLT1, FLT3, PDGFRB, PDGFRA | Phase 3 | Cervical Cancer; Triple-Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Breast Neoplasm … | May 2027 |
| GSK | IDRX-42 (GSK6042981, velzatinib) Receptor tyrosine kinase inhibitor | KIT, PDGFRA | Phase 3 | Gastrointestinal Neoplasms; Gastrointestinal Stromal Neoplasms | Nov 2027 |
| AB Science | Masitinib Fibroblast growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor | FGFR3, KIT, PDGFRB, PDGFRA | Phase 3 | Amyotrophic Lateral Sclerosis | Dec 2027 |
| Cogent Biosciences | CGT9486 FIP1L1-PDGFRα inhibitor | PDGFRA | Phase 3 | Advanced Gastrointestinal Stromal Tumors | Jan 2030 |
| M.D. Anderson Cancer Center | Sunitinib Malate Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Renal Cell Carcinoma; Malignant Neoplasms of Urinary Tract; Prostate Cancer | Dec 2026 |
| National Cancer Institute (NCI) | Sunitinib Malate Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Advanced Lymphoma; Metastatic Pancreatic Neuroendocrine Tumor | Dec 2026 |
| Avalyn Pharma | Nintedanib (AP02) Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor | PDGFRB, PDGFRA, FLT1, FLT4, KDR | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF); Systemic Sclerosis; Telangiectasia, Hereditary Hemorrhagic; Non Small Cell Lung Cancer … | Dec 2026 |
| Beijing Scitech-Mq Pharmaceuticals | ST-1898 Receptor tyrosine kinase (RTK) inhibitor targeting VEGFR2, c-MET, AXL, PDGFRA, RET, and KI | VEGFR2, MET, AXL, PDGFRA, RET | Phase 2 | Differentiated Thyroid Carcinoma; Unresectable or Metastatic Melanoma; Advanced Renal Cell Carcinoma | Dec 2026 |
| Sun Yat-sen University | Anlotinib Hydrochloride Multi-tyrosine kinase inhibitor targeting VEGFR, PDGFR, FLT1, KIT, and RET | VEGFR, PDGFRA, PDGFRB, FLT1, KIT | Phase 2 | Glioblastoma | Dec 2026 |
| Canadian Cancer Trials Group | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Advanced Rare Tumours | Dec 2026 |
| University of Miami | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Gastrointestinal Stromal Tumors | Dec 2026 |
| Sarcoma Alliance for Research through Collaboration | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Gastrointestinal Stromal Tumors | Jun 2027 |
| Tianjin Medical University Cancer Institute and Hospital | Anlotinib Hydrochloride multi-target tyrosine kinase inhibitor (VEGFR, PDGFR, FGFR inhibitor) | KDR, PDGFRA, FLT4 | Phase 2 | Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer | Jun 2027 |
| Fudan University | Sitravatinib Small molecule inhibitor of receptor tyrosine kinases | PDGFRA, KIT, RET, FLT3 | Phase 2 | Metastatic Breast Cancer | Jun 2027 |
| Mannkind | Nintedanib (MNKD-201) Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor | PDGFRB, PDGFRA, FLT1, FLT4, KDR | Phase 2 | Idiopathic Pulmonary Fibrosis | Dec 2027 |
| American Society of Clinical Oncology | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Lymphoma, Non-Hodgkin | Dec 2027 |
| Bai-Rong Xia | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Ovary Cancer | Dec 2027 |
| Memorial Sloan Kettering Cancer Center | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Osteosarcoma | Mar 2028 |
| Novartis | Midostaurin Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor | FLT3, KIT, PDGFRB, PDGFRA, PRKD3 | Phase 2 | FLT3-mutated Acute Myeloid Leukemia; AML/MDS; Acute Myeloid Leukemia | May 2029 |
| AstraZeneca | cediranib Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor | KIT, PDGFRB, PDGFRA, FLT1, FLT4 | Phase 1 | Solid Tumors; Fallopian Tube Clear Cell Adenocarcinoma; Cervical Cancer; Mismatch Repair Proficient Colorectal Cancer … | Dec 2026 |
| Betta Pharmaceuticals | X-82 Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor | PDGFRB, PDGFRA, FLT1, FLT4, KDR | Phase 1 | DDI (Drug-Drug Interaction); Hepatic Impairment (HI); Advanced Non-small Cell Lung Cancer (NSCLC); Vorolanib … | Jan 2027 |
| State University of New York at Buffalo | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 1 | Carcinoma, Renal Cell | Jul 2027 |
| University of Colorado, Denver | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 1 | Osteosarcoma | Aug 2027 |
| Telix Pharmaceuticals (Innovations) | 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx) anti-PDGFRA antibody labeled with zirconium-89 for diagnostic imaging | PDGFRA | Phase 1 | Soft Tissue Sarcoma | Oct 2027 |
| Rabin Medical Center | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 1 | Solid Tumors Refractory to Standard Therapy | Jan 2028 |
| Ono Pharmaceutical | Ripretinib (DCC-2618) Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor | KIT, PDGFRA | Phase 1 | Gastrointestinal Stromal Tumors | Feb 2028 |
Acute Myeloid Leukemia (9) Gastrointestinal Stromal Tumors (4) Colorectal Cancer (2) Hepatic Impairment (2) Renal Cell Carcinoma (RCC) (2) Pulmonary Arterial Hypertension (2) Osteosarcoma (2) Fallopian Tube Clear Cell Adenocarcinoma (2) Cervical Cancer (2) Fallopian Tube Carcinoma (2) TNBC - Triple-Negative Breast Cancer (2) GIST (2)
small molecule (24), antibody (4), mixed (4)
Deciphera Pharmaceuticals (2) Beijing Scitech-Mq Pharmaceuticals (1) Canadian Cancer Trials Group (1) Novartis (1) Tianjin Medical University Cancer Institute and Hospital (1) Exelixis (1) Ono Pharmaceutical (1) Avalyn Pharma (1) Gossamer Bio USA (1) Blueprint Medicines (1) Fudan University (1) Telix Pharmaceuticals (Innovations) (1) Daiichi Sankyo (1) Mannkind (1) Sun Yat-sen University (1) Memorial Sloan Kettering Cancer Center (1) University of Colorado, Denver (1) AstraZeneca (1) Sarcoma Alliance for Research through Collaboration (1) Jiangsu HengRui Medicine (1)
KIT (25) PDGFRB (21) FLT3 (15) CSF1R (14) FLT1 (6) FLT4 (5) KDR (4) MET (2) RET (2) FGFR3 (2) VEGFR2 (1) AXL (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.